دورية أكاديمية
أعرض في EDS

Genomic surveillance and vaccine response to the dominant SARS-CoV-2 XBB lineage in Rio Grande do Sul.

التفاصيل البيبلوغرافية
العنوان: Genomic surveillance and vaccine response to the dominant SARS-CoV-2 XBB lineage in Rio Grande do Sul.
المؤلفون: Piccoli BC; Laboratório de Biologia Molecular e Bioinformática Aplicadas a Microbiologia Clínica (LABIOMIC), Departamento de Análises Clínicas e Toxicológicas, Universidade Federal de Santa Maria, Rio Grande do Sul, Brazil., Y Castro TR; Laboratório de Biologia Molecular e Bioinformática Aplicadas a Microbiologia Clínica (LABIOMIC), Departamento de Análises Clínicas e Toxicológicas, Universidade Federal de Santa Maria, Rio Grande do Sul, Brazil., Tessele LF; Laboratório de Biologia Molecular e Bioinformática Aplicadas a Microbiologia Clínica (LABIOMIC), Departamento de Análises Clínicas e Toxicológicas, Universidade Federal de Santa Maria, Rio Grande do Sul, Brazil., Casarin BC; Laboratório de Biologia Molecular e Bioinformática Aplicadas a Microbiologia Clínica (LABIOMIC), Departamento de Análises Clínicas e Toxicológicas, Universidade Federal de Santa Maria, Rio Grande do Sul, Brazil., Seerig AP; Vigilância em SaúdeSecretaria Municipal da Saúde de Santa Maria, Rio Grande do Sul, Brazil., Vieira AA; Laboratório de Biologia Molecular e Bioinformática Aplicadas a Microbiologia Clínica (LABIOMIC), Departamento de Análises Clínicas e Toxicológicas, Universidade Federal de Santa Maria, Rio Grande do Sul, Brazil., Santos VT; Laboratório de Biologia Molecular e Bioinformática Aplicadas a Microbiologia Clínica (LABIOMIC), Departamento de Análises Clínicas e Toxicológicas, Universidade Federal de Santa Maria, Rio Grande do Sul, Brazil., Schwarzbold AV; Departamento de Clínica Médica, Universidade Federal de Santa Maria, Rio Grande do Sul, Brazil., Trindade PA; Laboratório de Biologia Molecular e Bioinformática Aplicadas a Microbiologia Clínica (LABIOMIC), Departamento de Análises Clínicas e Toxicológicas, Universidade Federal de Santa Maria, Rio Grande do Sul, Brazil. priscila.trindade@ufsm.br.
المصدر: Scientific reports [Sci Rep] 2024 Jul 22; Vol. 14 (1), pp. 16831. Date of Electronic Publication: 2024 Jul 22.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: SARS-CoV-2*/genetics , SARS-CoV-2*/immunology , COVID-19*/epidemiology , COVID-19*/immunology , COVID-19*/virology , COVID-19*/prevention & control , COVID-19 Vaccines*/immunology , Genome, Viral*, Humans ; Brazil/epidemiology ; Female ; Male ; Middle Aged ; Adult ; Aged ; Phylogeny ; Young Adult ; Adolescent ; Genomics/methods
مستخلص: The COVID-19 pandemic has been marked by novel viral variants, posing challenges to global public health. Recombination, a viral evolution mechanism, is implicated in SARS-CoV-2's ongoing evolution. The XBB recombinant lineage, known for evading antibody-mediated immunity, exhibits higher transmissibility without increased disease severity. We investigated the prevalence and genomic features of XBB in SARS-CoV-2-positive cases in Rio Grande do Sul (RS), Brazil. We sequenced 357 samples from epidemiological weeks (EW) 47/2022 to 17/2023, and included 389 publicly available sequences. Clinical and epidemiological data were obtained from DATASUS, e-SUS, and SIVEP GRIPE (data recording systems of the Brazilian Ministry of Health). Of these, 143 were classified as XBB and 586 were other Omicron lineages. In March 2023 (EW 10), XBB became dominant, accounting for 83.3% of cases. 97.7% of XBB-infected patients successfully recovered from the infection, with a low mortality rate (2.3%). Even after receiving three vaccine doses and having been previously infected, 59.5% of the patients experienced reinfection with XBB. However, for 54% of the individuals, the interval between their XBB infection and the last vaccine dose exceeded one year, potentially leading to a decline in antibody levels. In addition, we identified 90 mutations in RS circulating XBB, spread throughout the genome, notably in the Spike protein region associated with immune resistance. This study provides insights into the dynamics and impact of a recombinant variant becoming predominant for the first time in the state. Continued surveillance of SARS-CoV-2 genomic evolution is crucial for effective public health management.
(© 2024. The Author(s).)
References: Viruses. 2022 Dec 05;14(12):. (PMID: 36560720)
Vaccines (Basel). 2023 Mar 22;11(3):. (PMID: 36992294)
PLoS Pathog. 2023 Jan 23;19(1):e1011128. (PMID: 36689483)
Cell. 2023 Jan 19;186(2):279-286.e8. (PMID: 36580913)
Emerg Microbes Infect. 2022 Dec;11(1):18-29. (PMID: 34818119)
J Virol. 2023 Mar 30;97(3):e0001123. (PMID: 36877072)
N Engl J Med. 2023 Jan 5;388(1):89-91. (PMID: 36476720)
J Infect Public Health. 2021 Feb;14(2):169-178. (PMID: 33486372)
Science. 2021 Feb 5;371(6529):. (PMID: 33408181)
J Med Virol. 2023 Mar;95(3):e28625. (PMID: 36852665)
Cell Host Microbe. 2023 Jan 11;31(1):9-17.e3. (PMID: 36476380)
Cell Host Microbe. 2022 Feb 9;30(2):154-162.e5. (PMID: 35120605)
Glob Health Epidemiol Genom. 2022 May 18;2022:8551576. (PMID: 35655960)
Nature. 2021 Aug;596(7870):109-113. (PMID: 34182569)
Microbiol Spectr. 2024 Mar 5;12(3):e0383123. (PMID: 38315011)
Bioinformatics. 2012 Jun 15;28(12):1647-9. (PMID: 22543367)
Cell Rep. 2023 Jan 31;42(1):111995. (PMID: 36656713)
N Engl J Med. 2022 May 19;386(20):1910-1921. (PMID: 35320659)
Viruses. 2023 Jan 22;15(2):. (PMID: 36851526)
MedComm (2020). 2023 Mar 15;4(2):e239. (PMID: 36938325)
Nat Commun. 2023 May 16;14(1):2800. (PMID: 37193706)
CMAJ. 2023 Jan 23;195(3):E127-E128. (PMID: 36690363)
Nat Immunol. 2022 Jun;23(6):940-946. (PMID: 35534723)
J Clin Virol. 2022 Jun;150-151:105162. (PMID: 35461042)
J Clin Invest. 2023 May 15;133(10):. (PMID: 36951954)
Euro Surveill. 2023 Mar;28(13):. (PMID: 36995374)
Microorganisms. 2023 Jan 16;11(1):. (PMID: 36677521)
Comput Biol Med. 2021 Jun;133:104380. (PMID: 33872970)
Bioinformatics. 2018 Sep 15;34(18):3094-3100. (PMID: 29750242)
Cell Rep. 2023 May 30;42(5):112443. (PMID: 37104089)
Lancet Reg Health West Pac. 2023 Apr;33:100732. (PMID: 37125085)
Indian J Clin Biochem. 2022 Dec 17;:1-8. (PMID: 36569378)
N Engl J Med. 2022 Oct 6;387(14):1332-1333. (PMID: 36103455)
Viruses. 2022 Jun 07;14(6):. (PMID: 35746710)
فهرسة مساهمة: Keywords: COVID-19; Genome sequencing; Molecular epidemiology; Recombinant variant
المشرفين على المادة: 0 (COVID-19 Vaccines)
SCR Organism: SARS-CoV-2 variants
تواريخ الأحداث: Date Created: 20240722 Date Completed: 20240722 Latest Revision: 20240805
رمز التحديث: 20240805
مُعرف محوري في PubMed: PMC11263389
DOI: 10.1038/s41598-024-67828-7
PMID: 39039137
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-024-67828-7